Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Drops By 7.4%

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 836,600 shares, a decline of 7.4% from the December 15th total of 903,100 shares. Based on an average daily trading volume, of 420,900 shares, the days-to-cover ratio is currently 2.0 days.

Insider Activity

In other Biodesix news, Director Matthew Strobeck purchased 40,000 shares of the firm's stock in a transaction dated Tuesday, November 5th. The stock was bought at an average cost of $1.40 per share, with a total value of $56,000.00. Following the purchase, the director now directly owns 2,606,879 shares of the company's stock, valued at $3,649,630.60. The trade was a 1.56 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler acquired 200,000 shares of the business's stock in a transaction dated Wednesday, November 20th. The stock was acquired at an average cost of $1.17 per share, for a total transaction of $234,000.00. Following the transaction, the director now owns 31,094,935 shares of the company's stock, valued at $36,381,073.95. This represents a 0.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 315,000 shares of company stock worth $393,500 over the last quarter. 69.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently made changes to their positions in BDSX. Farallon Capital Management LLC acquired a new position in Biodesix during the second quarter worth $2,874,000. CVI Holdings LLC bought a new position in shares of Biodesix in the 2nd quarter valued at about $59,000. Perceptive Advisors LLC acquired a new position in shares of Biodesix during the 2nd quarter worth about $3,326,000. Perkins Capital Management Inc. increased its stake in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company's stock worth $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Biodesix in the 3rd quarter valued at about $262,000. Institutional investors own 20.96% of the company's stock.

Biodesix Stock Up 0.9 %

BDSX stock traded up $0.01 during midday trading on Friday, hitting $1.15. The company's stock had a trading volume of 195,487 shares, compared to its average volume of 222,300. The company's fifty day moving average price is $1.37 and its 200 day moving average price is $1.57. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. Biodesix has a twelve month low of $1.09 and a twelve month high of $2.21. The stock has a market capitalization of $167.29 million, a P/E ratio of -2.95 and a beta of 1.10.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The company had revenue of $18.15 million during the quarter, compared to analysts' expectations of $18.45 million. During the same quarter last year, the company earned ($0.12) EPS. As a group, equities research analysts predict that Biodesix will post -0.35 EPS for the current year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.